How 4th generation EGFR TKI differ from third generation TKI? – article suggested by Amol Akhade
Amol Akhade, Consultant medical oncologist and Hemato-oncologist, Reliance Hospitals, shared a post on LinkedIn:
“4th generation EGFR TKI.
How they differ from third generation TKI ?
All trials for 4 th generation tki .
Note first 3 were terminated by sponsors.
Plus go through PFS and OS Data for all generation egfr tki first line trials –
Which one has Maximum PFS ? Find out .
No it is not Osimertinib.
Good review in cancer treatment reviews by ESMO – European Society for Medical Oncology.”
Authors: Carla Corvaja, Ilaria Attili, Pamela Trillo Aliaga, Gianluca Spitaleri, Ester Del Signore and Filippo de Marinis.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023